10.1016/S1474-4422(13)70293-X 352 O'MahonyS
Specific triggers for medical consultation include achieving less than 5% body weight reduction after reaching the maintenance dose (for Wegovy, after 12 weeks at 2.4 mg as per FDA labeling), prolonged weight loss plateau despite adherence, or intolerable side effects preventing dose escalation to therapeutic levels
If you notice persistent or severe night sweats, it is a good idea to discuss them with your healthcare provider
The first test was administered in April 2022, and the last was in August 2023
The imbalance between M1 and M2 macrophages leads to inflammation, which is not only related to the function of the macrophages but also to the influence of macrophages on ferroptosis
Currently, there is no FDA-approved oral dose higher than 25 mg available